WuXi AppTec Co., Ltd. (OTCMKTS:WUXAY – Get Free Report) shares saw an uptick in trading volume on Friday. 54,913 shares traded hands during mid-day trading, an increase of 1,091% from the previous session’s volume of 4,612 shares. The stock last traded at $25.00 and had previously closed at $25.80.
Wall Street Analyst Weigh In
Separately, Zacks Research cut WuXi AppTec from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 5th. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, WuXi AppTec currently has a consensus rating of “Moderate Buy”.
Get Our Latest Report on WUXAY
WuXi AppTec Stock Down 3.8%
The business’s fifty day moving average price is $25.82 and its 200 day moving average price is $20.48.
About WuXi AppTec
WuXi AppTec is a contract research, development and manufacturing organization (CRDMO) that provides services to pharmaceutical, biotechnology and medical-device companies. Its offerings span the drug-development process, including early-stage discovery, medicinal and synthetic chemistry, biology research, analytical testing, preclinical studies, clinical research support, process development and commercial manufacturing.
The company supports a broad range of therapeutic programs, with capabilities covering small-molecule drugs, biologics, chemical and pharmaceutical products, and cell and gene therapies.
Featured Articles
- Five stocks we like better than WuXi AppTec
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for WuXi AppTec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WuXi AppTec and related companies with MarketBeat.com's FREE daily email newsletter.
